Peptio

Browse

Peptide library

Every peptide we have reviewed, with the strongest kind of evidence available for each one and whether any of it comes from human research.

18
catalogued
16
with human evidence
491
sources behind them
FiltersActive
Research status
Research area
Evidence
  • Afamelanotide

    Scenesse, Melanotan I, Melanotan-1, MT-1, CUV1647, NDP-MSH

    A synthetic alpha-MSH analogue approved as an implant for one rare light disease in adults. Melanotan I was a code name; products sold as it are not the drug.

    Human RCTApproved for a medical indicationskin hair / safety regulation
  • BPC-157

    BPC 157, PL-14736, PL 14736, PLD-116, PL-10, Bepecin, pentadecapeptide BPC 157

    A 15-amino-acid fragment of a gastric juice protein, studied mostly in rats for tendon and muscle healing. No randomised trial has shown a benefit in people.

    Case reportIn clinical trialsrecovery / performance
  • CJC-1295

    CJC-1295 DAC, DAC:GRF

    A synthetic analogue of growth hormone-releasing hormone. Two molecules share the name; only one was studied in people, for hormone levels.

    Human RCTDevelopment discontinuedperformance / safety regulation
  • Dihexa

    PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, Hexanoyl-Tyr-Ile-Ahx-NH2, ATH-1001

    A synthetic angiotensin IV analogue with no human study found. Its mechanism paper was retracted in 2025; FDA lists it as a withdrawn compounding nomination.

    AnimalNo published human datacognition / safety regulation
  • DSIP

    delta sleep-inducing peptide, delta sleep inducing peptide, delta-sleep-inducing peptide, emideltide, emideltide acetate, DSIP peptide, WAGGDASGE, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

    A nine-amino-acid peptide named for an EEG effect in rabbits. Small 1980s human sleep studies were mixed, and independent ones found little or no benefit.

    Human RCTIn clinical trialssleep / safety regulation
  • Elamipretide (SS-31)

    SS-31, SS31, MTP-131, Bendavia, Forzinity, RX-31, Ocuvia

    A synthetic mitochondrial tetrapeptide given FDA accelerated approval in 2025 for Barth syndrome only. No trial has tested it against ageing.

    Human RCTApproved for a medical indicationlongevity / safety regulation
  • Epitalon

    Epithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly, AEDG peptide

    A four-amino-acid peptide studied almost only by one Russian network. No trial with a clinical outcome was found; its lifespan data are from animals.

    Case reportPreclinical onlylongevity / sleep / safety regulation
  • GHK-Cu

    copper tripeptide-1, GHK copper, prezatide copper, glycyl-L-histidyl-L-lysine copper

    A three-amino-acid peptide bound to copper, used in skin care. Its human studies are topical; none injected GHK-Cu on its own or tested it systemically.

    Human RCTIn clinical trialsskin hair / safety regulation
  • Ipamorelin

    NNC 26-0161, Ipamorelin acetate

    A synthetic growth hormone secretagogue. Never approved; its one published clinical trial, in postoperative ileus, did not show a benefit.

    Human RCTDevelopment discontinuedperformance / safety regulation
  • Melanotan II

    Melanotan 2, Melanotan-II, MT-II, MTII, MT2

    A synthetic cyclic peptide sold for tanning. Its human trials total 23 men between 1996 and 2000, and none of the regulators checked has approved it.

    Case reportIn clinical trialsskin hair / safety regulation
  • MOTS-c

    MOTs-c, MOTs-C, MOTSc, MOTS-C, Mitochondrial-derived peptide MOTS-c, Mitochondrial open reading frame of the 12S rRNA-c

    A 16-amino-acid peptide encoded in mitochondrial DNA. Its metabolic and lifespan data come from mice; no human trial of it has reported results.

    Human obs.Preclinical onlylongevity / safety regulation
  • Retatrutide

    LY3437943, LY-3437943

    Investigational triple receptor agonist with published phase 3 trials. Not approved by FDA, EMA, the MHRA or the TGA, the four regulators checked.

    Human RCTIn clinical trialsweight management
  • Selank

    TKPRPGP, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TP-7, Selank acetate

    A seven-amino-acid tuftsin analogue. Its patient studies are small, Russian and without placebo; FDA lists it as a withdrawn compounding nomination.

    Case reportIn clinical trialscognition / safety regulation
  • Semaglutide

    Ozempic, Wegovy, Rybelsus

    A GLP-1 receptor agonist approved in the US and EU for type 2 diabetes and weight management, with cardiovascular and kidney outcome trials.

    Human RCTApproved for a medical indicationweight management
  • Semax

    Semaks, ACTH(4-7)-Pro-Gly-Pro, ACTH(4-7)PGP, MEHFPGP, Met-Glu-His-Phe-Pro-Gly-Pro

    A seven-amino-acid ACTH fragment analogue that FDA reports is registered in Russia. Its human studies are small, mostly Russian, and not placebo-randomised.

    Case reportIn clinical trialscognition / safety regulation
  • TB-500

    TB500, TB 500, Ac-LKKTETQ, TB-500 acetate, thymosin beta-4 fragment 17-23

    A seven-amino-acid fragment of thymosin beta-4, not the protein itself. No study has reported giving it to a human being.

    AnimalNo published human datarecovery / performance
  • Tesamorelin

    Egrifta, Egrifta SV, Egrifta WR, TH9507

    A growth hormone-releasing hormone analogue approved in the US for one use: excess abdominal fat in adults with HIV and lipodystrophy.

    MetaApproved for a medical indicationweight management / cognition
  • Tirzepatide

    LY3298176, Mounjaro, Zepbound

    Tirzepatide is a dual GIP and GLP-1 receptor agonist, approved in the US and the EU for type 2 diabetes and for weight management.

    Human RCTApproved for a medical indicationweight management